Tremfya®
Drug class
- Biologic/biosimilar
- IL-23 inhibitor
Generic name
Guselkumab
Safety
Efficacy
Convenience
Indications
Approved for moderate to severe Crohn's disease and moderate to severe ulcerative colitis in adults.
How it works
By inhibiting specific proteins that cause inflammation, biologic medications reduce disease activity and severity.
Drug interactions
CYP450 substrates. Avoid live vaccines.
Pre-treatment screening tests
Liver enzymes and bilirubin levels, age-appropriate vaccinations, tuberculosis, hepatitis panel.
Tests during screening
Liver enzymes and bilirubin levels, age-appropriate vaccinations, tuberculosis, and hepatitis panel.
Payment options
https://www.tremfya.com/ulcerative-colitis/savings-support/Route of administration
Side effects
Infections and signs of infection including fever, sweats, chills, coughs, muscle aches, weight loss, diarrhea, and burning during urination. Fatigue, vomiting, unexplained rash, yellowing of the skin or eyes, nausea, loss of appetite, dark urine.
Contraindications
Serious hypersensitivity to guselkumab or any component of the formulation.
Safety information
Symptoms of serious allergic reaction, like face swelling, fainting, dizziness, hives, shortness of breath. May increase risk of infection. Symptoms of infections (e.g., fever, cough, etc.) and headache, gastroenteritis, diarrhea, and fatigue.